Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

  • Bousquet J
  • Siergiejko Z
  • Świebocka E
 et al. 
  • 60

    Readers

    Mendeley users who have this article in their library.
  • 80

    Citations

    Citations of this article.

Abstract

The physician's global evaluation of treatment effectiveness (GETE) at 16 weeks has been shown to be the most effective assessment of response to omalizumab (XOLAIR®). This randomized, open-label, parallel-group study evaluated the persistency of treatment responder classification in patients receiving omalizumab added to optimized asthma therapy (OAT).

Author-supplied keywords

  • Allergic asthma
  • immunoglobulin E
  • omalizumab
  • persistency
  • response

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free